Table 1.
All | LV Hypertrophy | p value† | ||
---|---|---|---|---|
(n=353) | No (n=291) | Yes (n=62) | ||
Demographics | ||||
Age (yrs) | 64±12 | 64±12 | 63±12 | 0.80 |
Men | 191(54) | 157(54) | 34(55) | 0.90 |
BMI (g/m2) | 31±7 | 31±7 | 31±8 | 0.91 |
Historical Data (%) | ||||
Smoking | 150(42) | 123(42) | 27(44) | 0.89 |
Hypertension | 243(69) | 197(68) | 46(74) | 0.56 |
Diabetes mellitus | 126(36) | 93(32) | 33(53) | 0.006 |
Hypercholesterolemia | 194(55) | 158(54) | 36(58) | 0.79 |
CHF | 55(16) | 41(14) | 14(23) | 0.23 |
Prior MI | 126(36) | 98(34) | 28(45) | 0.09 |
Medication (%) | ||||
ACE inhibitor/ARB | 107(30) | 77(26) | 30(48) | 0.003 |
Statin | 106(30) | 90(31) | 16(26) | 0.62 |
β-blocker | 123(35) | 97(33) | 26(42) | 0.33 |
Hemodynamic | ||||
Rest HR | 73±14 | 73±14 | 73±14 | 0.86 |
Rest SBP | 142±23 | 141±22 | 144±26 | 0.42 |
Rest DBP | 79±13 | 79±12 | 78±18 | 0.83 |
Peak HR | 130±16 | 131±15 | 125±18 | 0.03 |
Peak SBP | 148±27 | 148±26 | 149±28 | 0.87 |
Peak DBP | 77±16 | 77±16 | 79±16 | 0.37 |
Cardiac MRI | ||||
LVEF (%) | 55±13 | 57±12 | 48±14 | <0.001 |
LV mass(g) | 139±47 | 124±32 | 207±47 | <0.001 |
LV mass index(g/m2) | 69±22 | 62±13 | 105±19 | <0.001 |
Inducible ischemia | 110(31) | 80(27) | 30(48) | 0.001 |
Event (%) | ||||
Hard event | 71(20) | 51(17) | 20(32) | 0.009 |
Cardiac death | 43(12) | 27(9) | 15(24) | <0.001 |
MI | 38(11) | 30(10) | 7(11) | 0.79 |
For continuous variables, data are presented as mean ± standard deviation. For dichotomous variables, the number and percentage of participants with the condition are shown.
LV hypertrophy defined as LV mass index >96 g/m2 and 77 g/m2 in men and women, respectively.
p value for comparison of patients with or without LVH
Abbreviations: ACE = Angiotensin-converting enzyme; ARB= Angiotensin receptor blocker; BMI= Body mass index; CHF= Congestive heart failure; DBP = diastolic blood pressure; LVEF= Left ventricular ejection fraction; HR= heart rate; MI= Myocardial infarction; SBP= systolic blood pressure